1887

Abstract

Viral vectors encoding heterologous vaccine antigens are potent inducers of cellular immune responses, but they are generally less efficient at stimulating humoral immunity. To improve the induction of antibody responses by Semliki Forest virus-based vaccines, a vector encoding a translation-enhancer element and a novel internal signal sequence for increased expression and secretion of soluble antigens was designed. Approximately tenfold more human immunodeficiency virus type 1 gp120 was secreted into culture supernatants of infected cells using the enhanced vector compared with the parental vector. This translated into a significant increase in gp120-specific antibodies in immunized mice, suggesting that antigen-expression levels from the parental vector are limiting for induction of antibody responses. These data encourage the use of the enhanced vector for elicitation of immune responses against heterologous antigens during vaccination.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.83060-0
2007-10-01
2020-01-28
Loading full text...

Full text loading...

/deliver/fulltext/jgv/88/10/2774.html?itemId=/content/journal/jgv/10.1099/vir.0.83060-0&mimeType=html&fmt=ahah

References

  1. Barnett, S. W., Lu, S., Srivastava, I., Cherpelis, S., Gettie, A., Blanchard, J., Wang, S., Mboudjeka, I., Leung, L. & other authors ( 2001; ). The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. J Virol 75, 5526–5540.[CrossRef]
    [Google Scholar]
  2. Berglund, P., Quesada-Rolander, M., Putkonen, P., Biberfeld, G., Thorstensson, R. & Liljeström, P. ( 1997; ). Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus. AIDS Res Hum Retroviruses 13, 1487–1495.[CrossRef]
    [Google Scholar]
  3. Berglund, P., Smerdou, C., Fleeton, M. N., Tubulekas, I. & Liljeström, P. ( 1998; ). Enhancing immune responses using suicidal DNA vaccines. Nat Biotechnol 16, 562–565.[CrossRef]
    [Google Scholar]
  4. Berglund, P., Fleeton, M. N., Smerdou, C. & Liljeström, P. ( 1999; ). Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice. Vaccine 17, 497–507.[CrossRef]
    [Google Scholar]
  5. Berglund, P., Finzi, D., Bennink, J. R. & Yewdell, J. W. ( 2007; ). Viral alteration of cellular translational machinery increases defective ribosomal products. J Virol 81, 7220–7229.[CrossRef]
    [Google Scholar]
  6. Binley, J. M., Sanders, R. W., Clas, B., Schuelke, N., Master, A., Guo, Y., Kajumo, F., Anselma, D. J., Maddon, P. J. & other authors ( 2000; ). A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J Virol 74, 627–643.[CrossRef]
    [Google Scholar]
  7. Boudet, F., Chevalier, M., Jourdier, T. M., Tartaglia, J. & Moste, C. ( 2001; ). Modulation of the antibody response to the HIV envelope subunit by co-administration of infectious or heat-inactivated canarypoxvirus (ALVAC) preparations. Vaccine 19, 4267–4275.[CrossRef]
    [Google Scholar]
  8. Brimnes, M. K., Bonifaz, L., Steinman, R. M. & Moran, T. M. ( 2003; ). Influenza virus-induced dendritic cell maturation is associated with the induction of strong T cell immunity to a coadministered, normally nonimmunogenic protein. J Exp Med 198, 133–144.[CrossRef]
    [Google Scholar]
  9. Earl, P. L., Broder, C. C., Long, D., Lee, S. A., Peterson, J., Chakrabarti, S., Doms, R. W. & Moss, B. ( 1994; ). Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities. J Virol 68, 3015–3026.
    [Google Scholar]
  10. Earl, P. L., Sugiura, W., Montefiori, D. C., Broder, C. C., Lee, S. A., Wild, C., Lifson, J. & Moss, B. ( 2001; ). Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140. J Virol 75, 645–653.[CrossRef]
    [Google Scholar]
  11. Farzan, M., Choe, H., Desjardins, E., Sun, Y., Kuhn, J., Cao, J., Archambault, D., Kolchinsky, P., Koch, M. & other authors ( 1998; ). Stabilization of human immunodeficiency virus type 1 envelope glycoprotein trimers by disulfide bonds introduced into the gp41 glycoprotein ectodomain. J Virol 72, 7620–7625.
    [Google Scholar]
  12. Fleeton, M. N., Sheahan, B. J., Gould, E. A., Atkins, G. J. & Liljeström, P. ( 1999; ). Recombinant Semliki Forest virus particles encoding the prME or NS1 proteins of louping ill virus protect mice from lethal challenge. J Gen Virol 80, 1189–1198.
    [Google Scholar]
  13. Forsell, M. N., Li, Y., Sundbäck, M., Svehla, K., Liljeström, P., Mascola, J. R., Wyatt, R. & Karlsson Hedestam, G. B. ( 2005; ). Biochemical and immunogenic characterization of soluble human immunodeficiency virus type 1 envelope glycoprotein trimers expressed by Semliki Forest virus. J Virol 79, 10902–10914.[CrossRef]
    [Google Scholar]
  14. Grundner, C., Li, Y., Louder, M., Mascola, J., Yang, X., Sodroski, J. & Wyatt, R. ( 2005; ). Analysis of the neutralizing antibody response elicited in rabbits by repeated inoculation with trimeric HIV-1 envelope glycoproteins. Virology 331, 33–46.[CrossRef]
    [Google Scholar]
  15. Hidmark, A. S., Nordström, E. K., Dosenovic, P., Forsell, M. N., Liljeström, P. & Karlsson Hedestam, G. B. ( 2006; ). Humoral responses against coimmunized protein antigen but not against alphavirus-encoded antigens require alpha/beta interferon signaling. J Virol 80, 7100–7110.[CrossRef]
    [Google Scholar]
  16. Huckriede, A., Bungener, L., Holtrop, M., de Vries, J., Waarts, B. L., Daemen, T. & Wilschut, J. ( 2004; ). Induction of cytotoxic T lymphocyte activity by immunization with recombinant Semliki Forest virus: indications for cross-priming. Vaccine 22, 1104–1113.[CrossRef]
    [Google Scholar]
  17. Hutchings, C. L., Gilbert, S. C., Hill, A. V. & Moore, A. C. ( 2005; ). Novel protein and poxvirus-based vaccine combinations for simultaneous induction of humoral and cell-mediated immunity. J Immunol 175, 599–606.[CrossRef]
    [Google Scholar]
  18. Karlsson, G. B. & Liljeström, P. ( 2004; ). Delivery and expression of heterologous genes in mammalian cells using self-replicating alphavirus vectors. Methods Mol Biol 246, 543–557.
    [Google Scholar]
  19. Leonard, C. K., Spellman, M. W., Riddle, L., Harris, R. J., Thomas, J. N. & Gregory, T. J. ( 1990; ). Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J Biol Chem 265, 10373–10382.
    [Google Scholar]
  20. Li, Y., Kappes, J. C., Conway, J. A., Price, R. W., Shaw, G. M. & Hahn, B. H. ( 1991; ). Molecular characterization of human immunodeficiency virus type 1 cloned directly from uncultured human brain tissue: identification of replication-competent and -defective viral genomes. J Virol 65, 3973–3985.
    [Google Scholar]
  21. Liljeström, P. & Garoff, H. ( 1991; ). Internally located cleavable signal sequences direct the formation of Semliki Forest virus membrane proteins from a polyprotein precursor. J Virol 65, 147–154.
    [Google Scholar]
  22. Lubeck, M. D., Natuk, R., Myagkikh, M., Kalyan, N., Aldrich, K., Sinangil, F., Alipanah, S., Murthy, S. C., Chanda, P. K. & other authors ( 1997; ). Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nat Med 3, 651–658.[CrossRef]
    [Google Scholar]
  23. Malkevitch, N. V. & Robert-Guroff, M. ( 2004; ). A call for replicating vector prime-protein boost strategies in HIV vaccine design. Expert Rev Vaccines 3, S105–S117.[CrossRef]
    [Google Scholar]
  24. McInerney, G. M., Kedersha, N. L., Kaufman, R. J., Anderson, P. & Liljeström, P. ( 2005; ). Importance of eIF2α phosphorylation and stress granule assembly in alphavirus translation regulation. Mol Biol Cell 16, 3753–3763.[CrossRef]
    [Google Scholar]
  25. Montefiori, D. C., Graham, B. S., Kliks, S. & Wright, P. F. ( 1992; ). Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gp160. NIAID AIDS Vaccine Clinical Trials Network. J Clin Immunol 12, 429–439.[CrossRef]
    [Google Scholar]
  26. Patterson, L. J., Malkevitch, N., Venzon, D., Pinczewski, J., Gomez-Roman, V. R., Wang, L., Kalyanaraman, V. S., Markham, P. D., Robey, F. A. & Robert-Guroff, M. ( 2004; ). Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting. J Virol 78, 2212–2221.[CrossRef]
    [Google Scholar]
  27. Sanders, R. W., Venturi, M., Schiffner, L., Kalyanaraman, R., Katinger, H., Lloyd, K. O., Kwong, P. D. & Moore, J. P. ( 2002a; ). The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol 76, 7293–7305.[CrossRef]
    [Google Scholar]
  28. Sanders, R. W., Vesanen, M., Schuelke, N., Master, A., Schiffner, L., Kalyanaraman, R., Paluch, M., Berkhout, B., Maddon, P. J. & other authors ( 2002b; ). Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol 76, 8875–8889.[CrossRef]
    [Google Scholar]
  29. Schulke, N., Vesanen, M. S., Sanders, R. W., Zhu, P., Lu, M., Anselma, D. J., Villa, A. R., Parren, P. W., Binley, J. M. & other authors ( 2002; ). Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein. J Virol 76, 7760–7776.[CrossRef]
    [Google Scholar]
  30. Shu, Y., Winfrey, S., Yang, Z. Y., Xu, L., Rao, S. S., Srivastava, I., Barnett, S. W., Nabel, G. J. & Mascola, J. R. ( 2006; ). Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs. Vaccine 25, 1398–1408.
    [Google Scholar]
  31. Sjöberg, E. M., Suomalainen, M. & Garoff, H. ( 1994; ). A significantly improved Semliki Forest virus expression system based on translation enhancer segments from the viral capsid gene. Biotechnology (N Y) 12, 1127–1131.[CrossRef]
    [Google Scholar]
  32. Smerdou, C. & Liljeström, P. ( 1999; ). Two-helper RNA system for production of recombinant Semliki Forest virus particles. J Virol 73, 1092–1098.
    [Google Scholar]
  33. Thompson, J. M., Whitmore, A. C., Konopka, J. L., Collier, M. L., Richmond, E. M., Davis, N. L., Staats, H. F. & Johnston, R. E. ( 2006; ). Mucosal and systemic adjuvant activity of alphavirus replicon particles. Proc Natl Acad Sci U S A 103, 3722–3727.[CrossRef]
    [Google Scholar]
  34. Yang, X., Farzan, M., Wyatt, R. & Sodroski, J. ( 2000; ). Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins. J Virol 74, 5716–5725.[CrossRef]
    [Google Scholar]
  35. Yang, X., Wyatt, R. & Sodroski, J. ( 2001; ). Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers. J Virol 75, 1165–1171.[CrossRef]
    [Google Scholar]
  36. Yang, X., Lee, J., Mahony, E. M., Kwong, P. D., Wyatt, R. & Sodroski, J. ( 2002; ). Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin. J Virol 76, 4634–4642.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.83060-0
Loading
/content/journal/jgv/10.1099/vir.0.83060-0
Loading

Data & Media loading...

Most cited articles

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error